Gland Pharma schedules analyst meeting on June 22, 2026
Gland Pharma has scheduled a one-on-one meeting with analysts and institutional investors for June 22, 2026, to discuss performance and strategy. The session involves SiMPL PMS arranged by Kotak Securities and was disclosed in compliance with SEBI regulations.
*this image is generated using AI for illustrative purposes only.
Gland Pharma has scheduled a one-on-one meeting with analysts and institutional investors for June 22, 2026. The company will engage with SiMPL PMS arranged by Kotak Securities during this session. These interactions are part of routine investor relations activities to discuss the company's performance and strategy with key market participants.
The disclosure was made in compliance with Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer, signed the intimation on June 17, 2026.
The schedule of the meetings is subject to change, and any modifications may occur due to exigencies on the part of the investors, analysts, or the company.
| Date | Investor/Analyst/Fund Name | Type of Meeting |
|---|---|---|
| June 22, 2026 | SiMPL PMS arranged by Kotak Securities | One-on-One Meeting |
Historical Stock Returns for Gland Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.21% | -2.89% | +17.87% | +33.24% | +25.80% | -28.94% |
What key strategic initiatives or growth drivers is Gland Pharma likely to highlight during the meeting?
How might the outcomes of this meeting influence investor sentiment or stock performance in the short term?
Could this meeting signal any upcoming partnerships, product launches, or market expansions?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
